NICE rejects Merck Serono's Erbitux, Roche's Avastin and Amgen's Vectibix for second line mCRC
This article was originally published in Scrip
Executive Summary
NICE, the health technology appraisal institute for England and Wales, has issued final draft guidance declining to recommend Merck Serono's Erbitux (cetuximab), Roche's Avastin (bevacizumab) and Amgen's Vectibix (panitumumab) for treating metastatic colorectal cancer (mCRC) that has progressed after first-line chemotherapy.